Exam 1: Intro to Antibiotics Flashcards

1
Q

General Approach

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Antimicrobial Targets

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Chemical Classes

A
  • Beta-lactams
  • Aminoglycosides
  • Tetracyclines
  • Etc
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Pharmacological Classes

A
  • Cell wall synthesis inhibitors
  • Proteins synthesis inhibitors
  • Etc
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Activity Classes

A
  • Gram +
  • Gram -
  • Aerobic
  • Anaerobic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Spectrum Classes

A

Narrow vs Broad

Spectrum

  • Broad spectrum
    • Likely to kill pathogen
    • Also likely to kill good microbes
  • Narrow spectrum
    • Lower chance of killing pathogen
    • Fewer adverse effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Spectrum

Considerations

A

1 pathogen can cause different diseases:

Severity of illness matters.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

De-escalation

A

Start Broad, Narrow Down

  • Give “best chance” abx empirically
  • Multiple abx may be required
  • Encouraged by institutional guidelines
  • Encourages broad-spectrum abx use
  • Spectrum is not the only variable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Selective Toxicity

A

Many abx work on pathways in bacteria that are similar but different than those in humans.

  • Differences in biochemistry
    • Methotrexate ⇒ ⊗ dihydrofolate reductase in most organisms
      • Not selective ⇒ more severe/common adverse effects
    • Trimethoprim ⇒ ⊗ dihydrofolate reductase in bacteria
  • Drug accumulation
    • Tetracycline ⇒ ⊗ 30S ribosome
      • Permeates bacterial membranes better than human membanes
      • Dose required to inhibit bacteria much lower than for humans
  • Cytology differences
    • Cell-wall synthesis inhibitors
    • Binds to target human cells lack
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Empiric Therapy

A

Selected before causative organism known.

Factors involved:

  • Likely pathogens
    • Which types cause suspected infection?
  • Drug activity
    • Which abx active against likely pathogens?
  • Pharmacokinetics
    • Which abx most active @ site of infection?
  • Patient factors
    • Adverse effects?
    • Patient vulnerable to atypical pathogens?
  • Cost
    • Which abx most economically feasible for patient and healthcare system?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Definitive Therapy

A

Selected once causative organism and susceptibility known.

Similar factors should be considered.

Therapy narrowed to avoid over-treating.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Abx Pharmacokinetics

A

Dictates utility of abx for various diseases in various settings:

  • Absorption
    • PO?
    • Too much or too little for success?
  • Distribution
    • Concentrate at site of infection?
    • Tissue penetration?
    • Patient factors?
  • Metabolism
    • Is drug metabolized?
    • Where, hepatic vs extra-hepatic?
    • Drug interactions?
  • Elimination
    • How is abx removed?
    • Renal dysfunciton or nephrotoxicity?
    • Extracorporeal elimination?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Tissue Penetration

A
  • Generally good
    • Urine, kidneys, soft tissues
  • Generally poor
    • Prostate, eye, abscess, vegetation
  • CNS
    • Variable
    • Often dependent on inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Patient Factors

A

Drug delivery can be influenced by:

  • DM
  • Peripheral vascular disease
  • Ascites
  • Burns
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Abx Pharmacodynamics

A

Bacteriostatic vs Bactericidal

  • Different types of activity for different organisms
  • Combo of static drugs may be cidal
  • In vitro vs in vivo effects
  • Activity based on normal achievable concentrations in humans
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Bacteriostatic

Agents

A
  • Inhibits growth
    • Do not necessarily kill the organism
  • Includes:
    • Macrolides
    • Tetracyclines
    • Clindamycin
    • Sulfonamides
    • Chloramphenicol
17
Q

Bactericidal

Agents

A
  • Actively kills organisms
  • Results in decreased numbers of bacteria
  • Preferred in neutropenia, meningitis, endocarditis, others
  • Includes:
    • Beta-lactams
    • Aminoglycosides
    • Fluoroquinolones
    • Nitroimidazoles
    • Cycyle lipopeptides
    • ? Vancomycin ⇒ “slowly” bactericidal
18
Q

Minimum Inhibitory Concentration

(MIC)

A

Lowest concentration at which visual growth is inhibited.

Predicts how likely drug will work in the body.

MIC50 ⇒ 50% of growth inhibited

MIC90 ⇒ 90% growth inhibited

19
Q

Minimum Bacterial Concentration

(MBC)

A

Lowest concentration in which 99.99% of bacteria are killed.

20
Q

Susceptibility

A
  • Susceptibility determined based on:
    • MIC values
    • Achievable concentrations in vivo
  • Low MIC/MBC ⇒ drug potent against pathogen
  • MIC values cannot be clinically compared between different drugs
    • Different doses
    • Different pharmacokinetics
    • Different pharmacodynamic parameters
21
Q

Concentration-dependent

Drugs

A
  • Level of activity dependent on Peak:MIC ratio or AUC:MIC ratio
    • e.g. how high above a therapeutic dose
  • Higher concentrations kill better
  • Ideal admin ⇒ infrequent, high doses
  • Ex:
    • Metronidazole
    • Aminoglycosides
    • Fluoroquinolones
    • Daptomycin
22
Q

Time-dependent

Drugs

A

“Concentration-independent drugs”

  • Level of activity dependent on time above MIC
  • Constant levels are ideal
  • Levels much higher than MIC do not result in better killing
  • Ideal admin ⇒ continuous infusion or frequent, smaller doses
  • Ex:
    • Beta-lactams
    • Vancomycin
    • Macrolides
    • Tetracyclines
23
Q

Post-Antibiotic Effect

(PAE)

A

Suppression of bacterial growth after abx exposure is over.

  • Most abx have PAE against Gram ⊕ cocci
  • Carbapenems, aminoglycosides, fluoroquinolones have PAE against Gram ⊖ bacilli
24
Q

Synergy

A

1 + 2 = 5

Methods of obtaining synergy:

  • Blockade of sequential metabolic steps
    • Ex. Trimethoprim + sulfamethoxazole
  • Inhibiting enzymatic inactivation
    • Ex. Ampicillin + Sulbactam
  • Enhancement of abx uptake
    • Ex. Gentamicin + Ampicillin
25
Q

Antagonism

A

1 + 2 = 1

Methods of antagonism:

  • Static agents inhibiting cidal activity of cell-wall active agents
    • Ex. Tetracycline + Amoxicillin
  • Induction of enzymatic inactivation
    • Ex. Ceftazidime (inducer) + Piperacillin (target)
26
Q

Adverse Effects

A
  1. Superinfections
    • Removal of susceptible strain may leave host at risk for infection by resistant strain
  2. Hypersensitivity
    • Manifestations
      • Rash, hives, anaphylaxis
      • Acute intestinal nephritis
      • Drug fever
    • Take allergy hx
27
Q

Antibiotic Resistance

A
  • Abx use high
    • 2nd most prescribed drug class
  • Human vs animal use
    • Therapeutic
    • Growth promotion
  • Perspectives differ
    • Patient, clinician, insurance, industry, society
  • 50% of abx prescribed are somehow inappropriate
  • Selected for by applying abx pressure
28
Q

Intrinsic Resistance

A

Resistance due to characteristics of species/genera

29
Q

Acquired Resistance

A

Not natural to bacteria.

Develop through random mutation or transfer or genetic material.

  • ↓ cellular membrane penetration
    • Drug structure
    • Porin channels
  • Efflux pumps
  • Cellular enzymes
    • Beta-lactamase
    • Aminoglycoside-modifying enzymes
  • Loss of target sites
30
Q

Acquisition

A
  • Random chance or plasmid/transposon mediated
  • Intrinsic susceptibility ⇒ acquired resistance
  • Can pass between bacteria & survive between generations
  • Bacteria typically do not become resistant during therapy
  • Resistance can be selected for or induced during therapy
31
Q

Overcoming

Abx Resistance

A
  • Dosing
    • Overcome low or intermediate level resistance with high doses
  • Drug modification
    • Augmentation of existing drugs
    • Enzyme inhibition
  • Combination therapy
  • Proper diagnosis
    • Infection vs colonization
    • Viral vs bacterial
  • Enduring adherence to regimen
  • De-escalation therapy